Japan's MHLW Enhances Role Of Innovation In Drug Pricing, USTR Says
This article was originally published in PharmAsia News
Executive Summary
WASHINGTON - Japan is giving more weight to innovation when pricing new drugs
You may also be interested in...
Chugai's Xeloda Obtains Additional Indications, Applies Tarceva For Pancreatic Cancer
The largest oncology drug maker in Japan, Roche's Japanese unit Chugai Pharmaceutical, obtained approvals for additional indications for anti-cancer drug Xeloda (capecitabine) and additional dosages for Avastin (bevacizumab). The company also submitted an application for an additional indication of pancreatic cancer for Tarceva (erlotinib), currently approved for non-small cell lung cancer in Japan
Chugai's Xeloda Obtains Additional Indications, Applies Tarceva For Pancreatic Cancer
The largest oncology drug maker in Japan, Roche's Japanese unit Chugai Pharmaceutical, obtained approvals for additional indications for anti-cancer drug Xeloda (capecitabine) and additional dosages for Avastin (bevacizumab). The company also submitted an application for an additional indication of pancreatic cancer for Tarceva (erlotinib), currently approved for non-small cell lung cancer in Japan
Drug Makers Say Japan's PMDA Drug Review Performance Improving
Japan's drug review body, the Pharmaceutical and Medical Device Agency, has significantly improved performance of the drug review process, demonstrated by shortened review times and higher satisfaction ratings, said the Office of Pharmaceutical Industry Research, a policy think tank under the industry trade association Japan Pharmaceutical Manufacturers Association